Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861265 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL861476 | 0.70 | MAPT (0.57) | LMNA | |
| Bromide SCHEMBL3992130 | 0.59 | MAPK14 (0.43) | — | |
| SCHEMBL24336172 | 0.57 | MAPK1 (0.33) | CHRNB2CHRNA4LMNA | |
| SCHEMBL25149001 | 0.56 | CDK9 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL23213871 | 0.56 | KDM4E (0.34) | PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL26907658 | 0.56 | XDH (0.32) | CHRNB2 | |
| SCHEMBL20125692 | 0.56 | KDM4E (0.35) | — | |
| SCHEMBL20710036 | 0.54 | MEN1 (0.32) | LMNA | |
| SCHEMBL16504005 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | CHRNB2 2500/4885CHRNA4 1201/4885FBP1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.